Beijing Innocare is a biopharmaceutical company developing treatments for cancer and autoimmune diseases. The company works on therapies targeting oncology and autoimmune indications. Healthcare investment firm Vivo Capital led a $55 million funding round in Beijing Innocare. CCB Capital also backed the round. The article does not provide details on the financing instrument or a breakdown of the proceeds. No operating metrics, past rounds, founding year, or location were disclosed in the article.

Total raised

$55M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2018